Parkinson’s disease with concomitant generalized anxiety disorder – case report Case report

Main Article Content

Jerzy Leszek

Abstract

Parkinson’s diseases, occuring most often between the ages of 50 and 60 years, on average at the age 58 years is a progressive degenerative disease of the central nervous system of global importance and serious consequences for public health. Its main symptoms are tremor at rest muscle stiffness and bradykinesia, i.e. slowness of movement (the so-called parkinsonian triad). Atrophic lessons of substantia nigra, located in the midbrain, responsible for the production of dopamine, contribute to the onset of symptoms of the disease. Patients with Parkinson’s diseases suffer from a variety of extra-motor symptoms often psychiatric disorders, especially panic or generalized anxiety. The author presents the case of 63 years old man diagnosed with Parkinson’s diseases 4 years ago, with quite a significant severity in the last 2 years. Left limb weakness (upper and lower) deepened and general slowing of movement developed then restless legs syndrome developed fully (specific sensations in the area of the feet and lower legs in the evening and night hours, temporarily decreasing when moving, walking, stretching the muscles). For about 6 months he have had attacks of anxiety and anxiety as well as a fully developed generalized anxiety disorder. The combination of levodopa and carbidopa and pregabalin was used, resulting in a reduction of slowness and stiffness as well as a significant reduction in anxiety and anxiety after approximately 8 weeks..

Article Details

How to Cite
Leszek , J. (2021). Parkinson’s disease with concomitant generalized anxiety disorder – case report. Medycyna Faktow (J EBM), 14(4(53), 441-443. https://doi.org/10.24292/01.MF.0421.14
Section
Articles

References

1. Ascherio D, Schwarzschil MA. The epidemiology of Parkinson’s diseases: risk factors and prevention. Lancet Neurol. 2016; 15(12): 1257-72.
2. Taylor J, Anderson WS, Brandt J et al. Neuropsychiatric complications of Parkinson’s Disease: Importance of Multidisciplinary Care. Am J Geriatr Psychiatry. 2016; 1171-80. http://doi.org/10.1016/j.jagp.2016.08.017.
3. Halliday GM, Stevens CH. Glia: initiators and progressors of pathology in Parkinson’s disease. Mov Disord. 2011; 26(1): 6-17.
4. Kordower JH, Brundin P. Lewy body pathology in long-term fetal nigral transplants: is Parkinson’s disease transmitted from one neural system to another? Neuropsycho-pharmacology. 2009; 34(1): 254.
5. LeWitt PA. Levodopa for the treatment of Parkinson’s disease. N Engl J Med. 2008; 359: 2468-76.
6. Sieminski M, Pyrzowski J. Zastosowanie pregabaliny w leczeniu zaburzeń lękowych uogólnionych. Psychiatria. 2017; 14(3): 121-8.